“…This difference in protein synthesis inhibition across different mRNAs is one possible explanation for the observed therapeutic index of cyclopenta[ b ]benzofurans [e.g., silvestrol ( 2 ) and the rocaglamide derivative, rohinitib ( 51 , Figure 6)] in mouse models. 56,63,72,79,85 Pelletier’s group first demonstrated that the translation initiation factor eIF4A was the likely target of the cyclopenta[ b ]benzofurans, using biochemical assays to show that 1- O -formylaglafoline ( 52 , Figure 6) and silvestrol ( 2 ) stimulated an abnormal interaction of eIF4A with mRNA and prevented successful assembly of the mRNA:eIF4A dimer with the eIF4F translation initiation complex. 66,72 As noted previously, this finding was separately confirmed by two groups using genetic and biochemical approaches.…”